Biomonitor
Copenhagen, Hovedstaden, Denmark
About Biomonitor
Biomonitor was founded in 2003 by Professor Klaus Bendtzen and Arsalan Kharazmi as a spinout from the University of Copenhagen and has since its inception grown rapidly. The foundation of the company is based on Professor Klaus Bendtzen’s many years of experience from his research work at the Copenhagen University Hospital on inflammation and immunology. Prof. Klaus Bendtzen discovered through his work how some patients form antibodies against those proteins and peptides that are used in biopharmaceutical products for the treatment of a range of chronic diseases. Antibodies can neutralize the biopharmaceuticals that patients receive and patients with antibodies thereby do not or only marginally benefit from such treatments so it became crucial to develop methods to monitor biopharmaceuticals.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $4.6M
- Last round: Series Unknown (Jun 2008)
- Website: biomonitor.dk
- Phone: 45 39 17 97 05
Industries & Categories
Biotechnology, Health Care, Hospital, Pharmaceutical
Canonical: https://fsome.com/organization/biomonitor-2570052 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.